Results 101 to 110 of about 108,718 (219)
Plasmodium vivax is the most geographically widespread and the dominant human malaria parasite in most countries outside of sub-Saharan Africa and, although it was classically recognized to cause benign infection, severe cases and deaths caused by P ...
Paulo Renato Totino +1 more
doaj +1 more source
Health Screening and Post‐Arrival Services for Refugee Children From Afghanistan
ABSTRACT Aim To examine refugee health screening and services for Afghan children in the unique context of emergency expedited humanitarian resettlement in Melbourne, Australia. Methods Retrospective audit of Afghan children who attended a specialist child refugee health service between August 2021–April 2024. Results Participants included 218 children
Amy Williamson +5 more
wiley +1 more source
Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study [PDF]
BACKGROUND: The erythrocyte polymorphism, Southeast Asian ovalocytosis (SAO) (which results from a 27-base pair deletion in the erythrocyte band 3 gene, SLC4A1Delta27) protects against cerebral malaria caused by Plasmodium falciparum; however, it is ...
Reeder, J. C. +113 more
core +1 more source
Molecular Detection of Malaria in South Punjab with Higher Proportion of Mixed Infections
Background: Malaria is well known for its fatalities worldwide, Plasmodium vivax and the Plasmodium falciparum are the two important species of malaria reported from Pakistan and creating lots of morbidities across the country.
Saba Shahzadi +5 more
doaj
Eukaryotes of the genus Plasmodium cause malaria, a parasitic disease responsible for substantial morbidity and mortality in humans. Yet, the nature and abundance of any viruses carried by these divergent eukaryotic parasites is unknown.
Justine Charon +9 more
doaj +1 more source
ABSTRACT Background Plasmodium vivax remains a challenge for malaria elimination in Nepal due to its ability to relapse. Radical cure with primaquine is effective but limited by poor adherence to the standard 14‐day low‐dose regimen. In 2022, the WHO recommended administering the same total dose (3.5 mg/kg) over 7 days to improve adherence.
Prakash Ghimire +18 more
wiley +1 more source
Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies [PDF]
Background: This study aimed to synthesize available evidence on the efficacy of dihydroartemisinin-piperaquine (DHP) in treating uncomplicated Plasmodium vivax malaria in people living in endemic countries.
Cho Naing (492196) +27 more
core +1 more source
Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. [PDF]
BACKGROUND: Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its malaria burden. Chloroquine resistance in P. vivax is emerging in Asia.
Faizullah Kaker +33 more
core +1 more source
Background The SD FK80 P.f/P.v Malaria Antigen Rapid Test (Standard Diagnostics, Korea) (FK80) is a three-band malaria rapid diagnostic test detecting Plasmodium falciparum histidine-rich protein-2 (HRP-2) and Plasmodium vivax-specific lactate ...
Van Esbroeck Marjan +5 more
doaj +1 more source
Severe vivax malaria: Newly recognised or rediscovered? [PDF]
Stephen Rogerson and Richard Carter discuss two new studies that challenge current dogma by suggesting that vivax malaria can cause severe ...
Carter Richard +7 more
core +2 more sources

